Brentuximab vedotin, nivolumab combination appears active for Hodgkin lymphoma

A combination of brentuximab vedotin with nivolumab appeared tolerable and safe among patients with relapsed or refractory Hodgkin lymphoma, according to results from a phase 1/phase 2 clinical trial presented at the ASH Annual Meeting and Exposition. The concept of trying to shy away from chemotherapy as salvage therapy is impressive, according to Andre Goy, M.D., MS, director of John Theurer Cancer Center, and chief of the Division of Lymphoma at Hackensack Meridian Health in New Jersey. “For decades, Hodgkin lymphoma has had the same treatment. We haven’t had anything really new,” Goy told HemOnc Today. “The idea [here] is to try and see if we can combine novel agents in the relapsed and refractory setting to maybe replace chemotherapy as salvage treatment. The results are impressive, despite a small cohort of patients.”

Read full article on